Preventing recurrent crashes without thrombocytosis

He explains preferring agents like rilzabrutinib or yonalimumab to reduce drops without causing thrombocytosis.

Play episode from 10:15

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!